drug_type
RELEVANT_DRUG
intervention_type
Monoclonal antibody (anti-CD38)
drug_description
Subcutaneous anti-CD38 IgG1 monoclonal antibody that targets CD38 on myeloma cells, mediating ADCC, CDC, and ADCP, and depleting CD38+ immunosuppressive cells.
nci_thesaurus_concept_id
C90578
nci_thesaurus_preferred_term
Isatuximab
nci_thesaurus_definition
A humanized IgG1 monoclonal antibody directed against the cell surface glycoprotein CD-38 with potential antineoplastic activity. Isatuximab specifically binds to CD38 on CD38-positive tumor cells. This may trigger antitumoral antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) and apoptosis eventually leading to cell lysis in CD38-expressing tumor cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies, and its expression has been correlated with poor prognosis.
drug_mesh_term
isatuximab
drug_category
CYTOTOXIC ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Anti-CD38 IgG1 monoclonal antibody that binds CD38 on malignant plasma cells and mediates Fc-dependent cytotoxicity (ADCC, CDC, ADCP) and apoptosis, resulting in lysis of CD38-expressing tumor cells; also depletes CD38+ immunosuppressive cells and can inhibit CD38 ectoenzyme activity, reducing adenosine-mediated immunosuppression.
drug_name
Isatuximab
nct_id_drug_ref
NCT05272826